Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

'Bionic eye' improves visual function, quality of life for people with retinitis pigmentosa

'Bionic eye' improves visual function, quality of life for people with retinitis pigmentosa

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Researchers identify previously unknown gene mutation that causes achromatopsia

Researchers identify previously unknown gene mutation that causes achromatopsia

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

Scientist receives $4.9 million CIRM grant to advance work in retinitis pigmentosa

Scientist receives $4.9 million CIRM grant to advance work in retinitis pigmentosa

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

UCI receives FDA consent to study stem cell-based treatment for retinitis pigmentosa in clinical trial

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

RetroSense Therapeutics receives Luis Villalobos Award

RetroSense Therapeutics receives Luis Villalobos Award

Research reveals stark variation in genetic tests for inherited eye disease in England

Research reveals stark variation in genetic tests for inherited eye disease in England

Study shows stark variation in genetic testing services for inherited eye conditions in England

Study shows stark variation in genetic testing services for inherited eye conditions in England

Wearable collision warning device may help patients with peripheral vision loss

Wearable collision warning device may help patients with peripheral vision loss

UCSF professor wins Vilcek Prize in Biomedical Science

UCSF professor wins Vilcek Prize in Biomedical Science

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Researchers discover retina protein crucial for vision

Researchers discover retina protein crucial for vision

Researchers uncover new gene tied to incurable eye disorder

Researchers uncover new gene tied to incurable eye disorder

Two UTHealth professors selected as AAAS Fellows for their efforts to prevent blindness

Two UTHealth professors selected as AAAS Fellows for their efforts to prevent blindness

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Light-activated diabetes drug: an interview with Dr David Hodson

Light-activated diabetes drug: an interview with Dr David Hodson